[go: up one dir, main page]

CO2019002159A2 - Análogos de amilina - Google Patents

Análogos de amilina

Info

Publication number
CO2019002159A2
CO2019002159A2 CONC2019/0002159A CO2019002159A CO2019002159A2 CO 2019002159 A2 CO2019002159 A2 CO 2019002159A2 CO 2019002159 A CO2019002159 A CO 2019002159A CO 2019002159 A2 CO2019002159 A2 CO 2019002159A2
Authority
CO
Colombia
Prior art keywords
amylin analogues
analogs
diabetes
disorders
treat
Prior art date
Application number
CONC2019/0002159A
Other languages
English (en)
Inventor
Dieter Wolfgang Hamprecht
Giacomo Fossati
Jesper Mosolff Mathiesen
Lise Giehm
Henrik Kofoed Munch
Jesper Skodborg VILLADSEN
Alexander Heim-Riether
Original Assignee
Zealand Pharma As
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As, Boehringer Ingelheim Int filed Critical Zealand Pharma As
Publication of CO2019002159A2 publication Critical patent/CO2019002159A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)

Abstract

La presente invención se refiere a análogos de amilina y su uso para tratar o prevenir varias enfermedades, afecciones o trastornos, que incluyen obesidad, ingesta excesiva de alimentos y enfermedades metabólicas asociadas tal como la diabetes. Los análogos pueden tener una buena estabilidad física y química, una buena solubilidad y una duración de acción prolongada y son muy adecuados para usar en forma de formulación líquida.
CONC2019/0002159A 2016-09-09 2019-03-07 Análogos de amilina CO2019002159A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16188024 2016-09-09
PCT/EP2017/072718 WO2018046719A1 (en) 2016-09-09 2017-09-11 Amylin analogues

Publications (1)

Publication Number Publication Date
CO2019002159A2 true CO2019002159A2 (es) 2019-07-31

Family

ID=56990230

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0002159A CO2019002159A2 (es) 2016-09-09 2019-03-07 Análogos de amilina

Country Status (26)

Country Link
US (5) US10071140B2 (es)
EP (2) EP4074729A1 (es)
JP (1) JP7064103B2 (es)
KR (1) KR102498393B1 (es)
CN (1) CN109863168B (es)
AR (1) AR109514A1 (es)
AU (1) AU2017322277B2 (es)
BR (1) BR112019004534A2 (es)
CA (1) CA3035958A1 (es)
CL (1) CL2019000575A1 (es)
CO (1) CO2019002159A2 (es)
DK (1) DK3510044T3 (es)
EA (1) EA201990360A1 (es)
ES (1) ES2901386T3 (es)
IL (1) IL264864B2 (es)
MA (1) MA46180A (es)
MX (1) MX2019002599A (es)
MY (1) MY197024A (es)
PE (2) PE20190963A1 (es)
PH (1) PH12019500474B1 (es)
SA (1) SA519401239B1 (es)
SG (1) SG11201901423XA (es)
TW (1) TWI784968B (es)
UA (1) UA123369C2 (es)
WO (1) WO2018046719A1 (es)
ZA (1) ZA201901253B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170126504A (ko) * 2015-03-18 2017-11-17 질랜드 파마 에이/에스 아밀린 유사체
AR109514A1 (es) 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
BR112021006823A2 (pt) 2018-10-11 2021-07-27 Intarcia Therapeutics, Inc. polipeptídeos análogos de amilina humana e métodos de uso
MX2022005661A (es) 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
AU2021322137A1 (en) 2020-08-07 2023-01-19 Boehringer Ingelheim International Gmbh Soluble NPY2 receptor agonists
TW202400632A (zh) 2021-03-03 2024-01-01 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
TW202346323A (zh) 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽
CA3257452A1 (en) * 2022-05-27 2025-04-15 Hangzhou Sciwind Biosciences Co., Ltd. ANALOGUE OF HUMAN AMYLIN, DERIVATIVES AND USES THEREOF
US20240335513A1 (en) 2022-05-30 2024-10-10 Zealand Pharma A/S Liquid formulations of amylin analogues
CN119343368A (zh) * 2022-07-29 2025-01-21 杭州九源基因工程股份有限公司 一种人胰淀素多肽衍生物及其用途
CA3266672A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S POLYTHERAPY
WO2024261076A1 (en) 2023-06-21 2024-12-26 Zealand Pharma A/S Weight loss
TW202515598A (zh) 2023-06-21 2025-04-16 丹麥商西蘭製藥公司 具有增進性能之類似物
AU2024306538A1 (en) 2023-06-30 2025-12-04 Zealand Pharma A/S Combination therapy
WO2025120001A1 (en) 2023-12-04 2025-06-12 Zealand Pharma A/S Amylin analogues for reducing consumption of high-fat food
WO2025120002A1 (en) 2023-12-04 2025-06-12 Zealand Pharma A/S Petrelintide for reducing weight whilst preserving lean mass
WO2025168049A1 (zh) * 2024-02-07 2025-08-14 江苏恒瑞医药股份有限公司 胰岛淀粉样多肽类似物及其医药用途
WO2025242620A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Polypeptide combinations and uses thereof
WO2025262301A1 (en) 2024-06-20 2025-12-26 Zealand Pharma A/S Petrelintide for use in the treatment of obesity, diabetes or a disease linked to obesity or diabetes, or of reducing body weight, inhibiting weight gain or reducing food intake
CN119161446B (zh) * 2024-11-22 2025-02-14 杭州诺泰诺和生物医药科技有限公司 胰淀素类似物的制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
WO1992015317A1 (en) 1991-03-08 1992-09-17 Amylin Pharmaceuticals, Inc. Synthetic preparation of amylin and amylin analogues
DK0567626T3 (da) 1991-11-19 2001-12-17 Amylin Pharmaceuticals Inc Amylin-agonist-peptider og anvendelse deraf
CZ69596A3 (en) 1993-09-07 1997-06-11 Amylin Pharmaceuticals Inc Application of amylin, amylin agonist, amylin analog agonist or amylin antagonist for preparing a pharmaceutical preparation used for the control of gastrointestinal motility
EP1826216A1 (en) 1996-08-30 2007-08-29 Novo Nordisk A/S Glp-1 derivatives
EP0929567B1 (en) 1996-09-09 2005-03-02 Zealand Pharma A/S Solid-phase peptide synthesis
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
CA2206028C (en) 1997-06-04 2006-10-03 Frantisek Ziak Fitness-balance board
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO1999034764A2 (en) * 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
DE60040333D1 (de) 1999-03-17 2008-11-06 Novo Nordisk As Verfahren zur acylierung von peptiden und proteinen
EP1631308B1 (en) 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
RU2378285C2 (ru) 2004-02-11 2010-01-10 Амилин Фармасьютикалз, Инк. Гибридные полипептиды с селектируемыми свойствами
NZ549332A (en) * 2004-02-11 2008-11-28 Amylin Pharmaceuticals Inc Amylin family peptides and methods for making and using them
DE102004051014A1 (de) 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
JP5252435B2 (ja) 2006-03-15 2013-07-31 ノボ・ノルデイスク・エー／エス アミリン誘導体
GEP20135944B (en) 2007-02-15 2013-10-25 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
ATE520714T1 (de) 2007-06-15 2011-09-15 Zealand Pharma As Glucagonanaloga
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
WO2010046357A1 (en) 2008-10-21 2010-04-29 Novo Nordisk A/S Amylin derivatives
WO2010070253A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
WO2010070251A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
WO2010070255A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
AU2008365556A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
WO2010107874A2 (en) 2009-03-17 2010-09-23 Amylin Pharmaceuticals, Inc. Methods for affecting body composition using amylin agonists
CN104961822A (zh) 2009-07-13 2015-10-07 西兰制药公司 酰化胰高血糖素类似物
JP5850848B2 (ja) 2009-11-25 2016-02-03 ノヴォ ノルディスク アー／エス ポリペプチドの製造方法
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
AU2011269430A1 (en) 2010-06-24 2013-01-10 Zealand Pharma A/S Glucagon analogues
CN103596973A (zh) 2011-06-10 2014-02-19 诺沃—诺迪斯克有限公司 多肽
BR112014015681A2 (pt) 2011-12-23 2019-09-24 Boehringer Ingelheim Int análogos de glucagon
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
ES2640285T3 (es) 2012-04-19 2017-11-02 Novo Nordisk A/S Análogos de amilina humana
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
BR102013017626A2 (pt) 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
AR097701A1 (es) 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
JP2016208556A (ja) 2013-10-03 2016-12-08 三菱電機株式会社 デマンド予測装置及びデマンド予測方法
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CN119119233A (zh) 2013-10-17 2024-12-13 西兰制药公司 酰化胰高血糖素类似物
TW201625605A (zh) 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類
EP3137494B1 (en) 2014-05-02 2021-08-04 The Research Foundation for The State University of New York Islet amyloid polypeptides with improved solubility
TW201625671A (zh) 2014-09-04 2016-07-16 諾佛 儂迪克股份有限公司 新穎澱粉素及降鈣素受體促效劑
MA41202A (fr) 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
KR20170126504A (ko) 2015-03-18 2017-11-17 질랜드 파마 에이/에스 아밀린 유사체
AR109514A1 (es) * 2016-09-09 2018-12-19 Zealand Pharma As Análogos de amilina
WO2018144671A1 (en) 2017-02-01 2018-08-09 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same

Also Published As

Publication number Publication date
PE20241305A1 (es) 2024-06-24
EP4074729A1 (en) 2022-10-19
ES2901386T3 (es) 2022-03-22
ZA201901253B (en) 2022-10-26
AU2017322277B2 (en) 2021-11-11
US10071140B2 (en) 2018-09-11
US20180071366A1 (en) 2018-03-15
KR20190045333A (ko) 2019-05-02
UA123369C2 (uk) 2021-03-24
BR112019004534A2 (pt) 2019-06-25
US20190134159A1 (en) 2019-05-09
SG11201901423XA (en) 2019-03-28
US20210346468A1 (en) 2021-11-11
US20250064895A1 (en) 2025-02-27
US20200188485A1 (en) 2020-06-18
CA3035958A1 (en) 2018-03-15
CN109863168B (zh) 2023-04-18
EA201990360A1 (ru) 2019-09-30
US12083164B2 (en) 2024-09-10
IL264864B1 (en) 2023-06-01
MX2019002599A (es) 2019-09-18
WO2018046719A1 (en) 2018-03-15
SA519401239B1 (ar) 2023-07-09
IL264864B2 (en) 2023-10-01
IL264864A (es) 2019-04-30
AU2017322277A1 (en) 2019-03-28
TW201811818A (zh) 2018-04-01
PH12019500474B1 (en) 2023-12-06
US11382956B2 (en) 2022-07-12
PE20190963A1 (es) 2019-07-08
MY197024A (en) 2023-05-22
CL2019000575A1 (es) 2019-05-10
DK3510044T3 (da) 2021-12-13
MA46180A (fr) 2021-03-24
TWI784968B (zh) 2022-12-01
PH12019500474A1 (en) 2019-08-05
JP2019534248A (ja) 2019-11-28
AR109514A1 (es) 2018-12-19
CN109863168A (zh) 2019-06-07
JP7064103B2 (ja) 2022-05-10
EP3510044A1 (en) 2019-07-17
KR102498393B1 (ko) 2023-02-13
EP3510044B1 (en) 2021-11-24
NZ751286A (en) 2024-05-31

Similar Documents

Publication Publication Date Title
CO2019002159A2 (es) Análogos de amilina
CO2017008870A2 (es) Análogos de amilina
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
ECSP19043725A (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
SV2016005257A (es) Benzimidazol-2-aminas como inhibidores de midh1
MX382671B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
UY35573A (es) Derivados de sulfamoilpirrolamida y su uso como m edicamentos para el tratamiento de la hepatitis b
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
MX381069B (es) Profármacos de carbidopa y l-dopa y métodos de uso.
ECSP15014941A (es) Compuestos antivíricos para el vsr
MX383715B (es) Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas.
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
ECSP20011578A (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática
MX2018003700A (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos.
SV2016005330A (es) Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cã�ncer
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
CR20150390A (es) Inhibidores de la yodoproteina basada en 2,3-dihidroimidazol[1,2-c]pirimidin-5(1-h)-ona-asociada a la fosfolipasa a2 (lp-pla2)
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
AR103350A1 (es) Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CO2017007007A2 (es) Análogos de calcitonina
CL2018002848A1 (es) Formulaciones liquidas de fosfoplatino